Literature DB >> 30375183

Depression-like symptoms of withdrawal in a genetic mouse model of binge methamphetamine intake.

Shkelzen Shabani1,2, Bryan Schmidt2, Bikalpa Ghimire2, Sydney K Houlton2, Laura Hellmuth2, Erika Mojica2, Tamara J Phillips3,4.   

Abstract

Binge methamphetamine (MA) users have higher MA consumption, relapse rates and depression-like symptoms during early periods of withdrawal, compared with non-binge users. The impact of varying durations of MA abstinence on depression-like symptoms and on subsequent MA intake was examined in mice genetically prone to binge-level MA consumption. Binge-level MA intake was induced using a multiple-bottle choice procedure in which mice were offered one water drinking tube and three tubes containing increasing concentrations of MA in water, or four water tubes (control group). In two studies, depression-like symptoms were measured using a tail-suspension test and a subsequent forced-swim test, after forced abstinence of 6 and 30 hours from a 28-day course of chronic MA intake. An additional study measured the same depression-like symptoms, as well as MA intake, after prolonged abstinence of 1 and 2 weeks. MA high drinking mice and one of their progenitor strains DBA/2J escalated their MA intake with increasing MA concentration; however, MA high drinking mice consumed almost twice as much MA as DBA/2J mice. Depression-like symptoms were significantly higher early after MA access was withdrawn, compared to levels in drug-naïve controls, with more robust effects of MA withdrawal observed in MA high drinking than DBA/2J mice. When depression-like symptoms were examined after 1 or 2 weeks of forced abstinence in MA high drinking mice, depression-like symptoms dissipated, and subsequent MA intake was high. The MA high drinking genetic mouse model has strong face validity for human binge MA use and behavioral sequelae associated with abstinence.
© 2018 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Keywords:  4-bottle choice; addiction; forced abstinence; forced-swim test; selected-lines; tail-suspension test

Mesh:

Substances:

Year:  2018        PMID: 30375183      PMCID: PMC6399044          DOI: 10.1111/gbb.12533

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  51 in total

1.  Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents.

Authors:  John F Cryan; Daniel Hoyer; Athina Markou
Journal:  Biol Psychiatry       Date:  2003-07-01       Impact factor: 13.382

2.  Binge use and sex and drug use behaviors among HIV(-), heterosexual methamphetamine users in San Diego.

Authors:  W Susan Cheng; Richard S Garfein; Shirley J Semple; Steffanie A Strathdee; James K Zians; Thomas L Patterson
Journal:  Subst Use Misuse       Date:  2010       Impact factor: 2.164

3.  Methamphetamine Addiction Vulnerability: The Glutamate, the Bad, and the Ugly.

Authors:  Karen K Szumlinski; Kevin D Lominac; Rianne R Campbell; Matan Cohen; Elissa K Fultz; Chelsea N Brown; Bailey W Miller; Sema G Quadir; Douglas Martin; Andrew B Thompson; Georg von Jonquieres; Matthias Klugmann; Tamara J Phillips; Tod E Kippin
Journal:  Biol Psychiatry       Date:  2016-10-13       Impact factor: 13.382

4.  Sensitivity to rewarding or aversive effects of methamphetamine determines methamphetamine intake.

Authors:  S Shabani; C S McKinnon; C Reed; C L Cunningham; T J Phillips
Journal:  Genes Brain Behav       Date:  2011-05-31       Impact factor: 3.449

Review 5.  The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice.

Authors:  John F Cryan; Cedric Mombereau; Annick Vassout
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

6.  Status of methamphetamine users 2-5 years after outpatient treatment.

Authors:  Richard A Rawson; Alice Huber; Paul Brethen; Jeanne Obert; Vikas Gulati; Steven Shoptaw; Walter Ling
Journal:  J Addict Dis       Date:  2002

7.  A dysphoric-like state during early withdrawal from extended access to methamphetamine self-administration in rats.

Authors:  Choon-Gon Jang; Timothy Whitfield; Gery Schulteis; George F Koob; Sunmee Wee
Journal:  Psychopharmacology (Berl)       Date:  2012-09-25       Impact factor: 4.530

Review 8.  Conflation of cocaine seeking and cocaine taking responses in IV self-administration experiments in rats: methodological and interpretational considerations.

Authors:  David C S Roberts; Amanda Gabriele; Benjamin A Zimmer
Journal:  Neurosci Biobehav Rev       Date:  2013-05-10       Impact factor: 8.989

9.  Antidepressant-like effects in various mice strains in the tail suspension test.

Authors:  Nadège Ripoll; Denis Joseph Paul David; Eric Dailly; Martine Hascoët; Michel Bourin
Journal:  Behav Brain Res       Date:  2003-08-14       Impact factor: 3.332

Review 10.  Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.

Authors:  Janet L Neisewander; Timothy H C Cheung; Nathan S Pentkowski
Journal:  Neuropharmacology       Date:  2013-08-23       Impact factor: 5.250

View more
  7 in total

1.  Optimizing outpatient treatment outcomes among methamphetamine-using gay and bisexual men through a computerized depression intervention.

Authors:  Jesse B Fletcher; Cathy J Reback
Journal:  J Subst Abuse Treat       Date:  2021-11-14

2.  Non-genetic factors that influence methamphetamine intake in a genetic model of differential methamphetamine consumption.

Authors:  A M Stafford; C Reed; T J Phillips
Journal:  Psychopharmacology (Berl)       Date:  2020-08-24       Impact factor: 4.530

3.  The motivational valence of methamphetamine relates inversely to subsequent methamphetamine self-administration in female C57BL/6J mice.

Authors:  Gabriella Shab; Elissa K Fultz; Ariana Page; Michal A Coelho; Lindsey W Brewin; Nicholas Stailey; Chelsea N Brown; Camron D Bryant; Tod E Kippin; Karen K Szumlinski
Journal:  Behav Brain Res       Date:  2020-10-11       Impact factor: 3.332

4.  Taar1 gene variants have a causal role in methamphetamine intake and response and interact with Oprm1.

Authors:  Alexandra M Stafford; Cheryl Reed; Harue Baba; Nicole Ar Walter; John Rk Mootz; Robert W Williams; Kim A Neve; Lev M Fedorov; Aaron J Janowsky; Tamara J Phillips
Journal:  Elife       Date:  2019-07-09       Impact factor: 8.140

5.  Confirmation of a Causal Taar1 Allelic Variant in Addiction-Relevant Methamphetamine Behaviors.

Authors:  Tamara J Phillips; Tyler Roy; Sara J Aldrich; Harue Baba; Jason Erk; John R K Mootz; Cheryl Reed; Elissa J Chesler
Journal:  Front Psychiatry       Date:  2021-08-26       Impact factor: 4.157

Review 6.  Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail.

Authors:  Hanis Mohammad Hazani; Isa Naina Mohamed; Mustapha Muzaimi; Wael Mohamed; Mohamad Fairuz Yahaya; Seong Lin Teoh; Rashidi Mohamed Pakri Mohamed; Mohd Fadzli Mohamad Isa; Sundus Mansoor Abdulrahman; Ravi Ramadah; Mohammad Rahim Kamaluddin; Jaya Kumar
Journal:  Front Pharmacol       Date:  2022-04-07       Impact factor: 5.988

7.  Prolonged Peripheral Immunosuppressive Responses as Consequences of Random Amphetamine Treatment, Amphetamine Withdrawal and Subsequent Amphetamine Challenges in Rats.

Authors:  Wojciech Glac; Joanna Dunacka; Beata Grembecka; Grzegorz Świątek; Irena Majkutewicz; Danuta Wrona
Journal:  J Neuroimmune Pharmacol       Date:  2021-02-13       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.